Phaseline

Targets › RSVG

RSVG: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Vaccines; next expected readout Feb 2027.

Open in Phaseline: the race on RSVG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Duke UniversityNirsevimab
Fusion glycoprotein F0 inhibitor
RSVGPhase 4FeverFeb 2027

Conditions

Fever (1)

Modalities

other (1)

Companies

Duke University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.